A phase II multicenter non-randomized study to assess safety, toxicity and clinical activity of the association of bortezomib(Velcade) with rituximab in relapsed/refractory indolent non follicular and mantle-cell non-Hodgkin lymphoma.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 27 Jan 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
- 27 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.